Platform Technology

LifeSplice's platform technology uses a highly-targeted approach for treating neurological and a wide range of non-neurological diseases.

LifeSplice develops novel splice modulating oligomers (SMOs) that directly modulate dysregulated pre-mRNA splicing and alternative splicing which are both frequently linked to severe neurological disorders and a broad range of non-neurological diseases.

LifeSplice's SMOs therapeutic mechanism functions through the re-balancing and normalization of natural pre-mRNA splicing.

An example of alternative splicing of a gene and the modulation of alternative splicing by an SMO is demonstrated in the diagrams below.

Image Image2